IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Anupam Rama - JPMorgan - Analyst : (Event Instructions) Maybe I'll kick off. Yujiro, can you talk a little bit about the recently in-licensed DLL3 program? Why was that a strategic interest to you? Why you're excited about it? It's a hot therapeutic area and we've seen some activity in the space.

Question: Anupam Rama - JPMorgan - Analyst : And I guess if I just think about the history of the company, the DLL3 and then the one that comes to mind is daro, right? Darovasertib, you got through business development. And largely beyond that, the pipeline has been internally from the synthetic lethality pipeline, how do we think about your openness to business development and versus focusing on your R&D engine internally?

Question: Anupam Rama - JPMorgan - Analyst : So maybe just to summarize, you look at BD as a way to accelerate kind of what you have internally already combinations or -- REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 14, 2025 / 1:15AM, IDYA.OQ - IDEAYA Biosciences Inc at JPMorgan Healthcare Conference

Question: Anupam Rama - JPMorgan - Analyst : Questions from the audience? Unidentified Participant 1 (inaudible - microphone inaccessible)

Question: Anupam Rama - JPMorgan - Analyst : Talking about PARG.

Question: Anupam Rama - JPMorgan - Analyst : Additional questions from the audience? Maybe I could ask a broad question on darovasertib, which is kind of when you look at the totality of what you have in metastatic and you look at what you have in the neoadjuvant setting, what do you think are the most misunderstood points by the Street on that program specifically? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 14, 2025 / 1:15AM, IDYA.OQ - IDEAYA Biosciences Inc at JPMorgan Healthcare Conference

Question: Anupam Rama - JPMorgan - Analyst : Questions from the audience? Unidentified Participant 1 Given your extensive expertise and the library compounds from the synthetic lethality space and then your recent transition into acquiring some ADCs, has there been a consideration of applying the two technologies on the same sort of dual payload synthetic lethality ADCs? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 14, 2025 / 1:15AM, IDYA.OQ - IDEAYA Biosciences Inc at JPMorgan Healthcare Conference

Question: Anupam Rama - JPMorgan - Analyst : Additional questions from the audience? Go ahead. Unidentified Participant 2 You're talking about lots of combination with 161 with ADCs, but the two ADCs you acquired from China is too early in terms of clinical implication. So I don't know which ADC you're going to combination with 101 at the beginning.

Question: Anupam Rama - JPMorgan - Analyst : Questions from the audience? Unidentified Participant 3 Maybe one for me. Just what are the final gating factors to getting alignment with the agency on the uveal melanoma study? I think the guidance is first half, right?